Company Filing History:
2 out of 2 
1 out of 1,745 
1 out of 42 Years Active: 2018
Title: Innovative Contributions of Bernardin Akagah
Introduction
Bernardin Akagah, an accomplished inventor based in Massy, France, has made significant strides in the field of pharmaceuticals with a focus on macrophage migration inhibitory factor (MIF) inhibitors. His work has led to the development of vital compounds aimed at treating various disorders related to MIF and pulmonary hypertension.
Latest Patents
Bernardin Akagah holds two notable patents that reflect his innovative contributions. The first patent involves MIF inhibitors, specifically the compounds of Formula (I′) and their use as inhibitors of macrophage migration inhibitory factor (MIF). This breakthrough has potential applications in treating disorders associated with MIF. The second patent pertains to the use of these compounds, as well as pharmaceutical compositions, in managing acute or chronic pulmonary hypertension. This invention focuses on the utilization of compounds of general Formula I and their pharmaceutically acceptable enantiomers, salts, or solvates for therapeutic interventions in affected subjects.
Career Highlights
Throughout his career, Bernardin has been associated with Mifcare, where he has demonstrated his expertise and commitment to innovation in medical research and development. His work has opened new avenues for treatment strategies, making a marked impact in the field of pharmaceuticals.
Collaborations
Bernardin Akagah has collaborated with several talented individuals in his field, including Gael Jalce and Gaël Jalce. These collaborations have played an essential role in advancing his research and innovations, contributing to the broader scientific community.
Conclusion
With his focus on developing MIF inhibitors, Bernardin Akagah is paving the way for promising treatment options in managing conditions associated with MIF and pulmonary hypertension. His innovative patents and collaborations underscore his commitment to advancements in medical science, reinforcing the importance of ongoing research and development in the pharmaceutical industry.